Summary
This meta-analysis aimed to comprehensively assess the efficacy and safety of hepatic resection combined with radiofrequency ablation versus hepatic resection (HR) alone for the treatment of multifocal hepatocellular carcinomas (HCC). A literature search was conducted from the database including MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and China Biology Medicine (CBM) disc. The primary outcomes included the 1-, 3-, 5-year overall survival (OS) and disease-free survival (DFS) rate. The secondary outcomes contained the intraoperative parameters and postoperative adverse events (AEs). These parameters were all analyzed by RevMan 5.3 software. After carefully screening relevant studies, four retrospective studies of high quality involving 466 patients (197 in the combined group and 269 in the HR group) were included in this study. The pooled results showed that the 1-, 3-, 5-year OS rate in the combined group were comparable with those in the HR group (OR=0.77, 0.96, 0.88; P=0.33, 0.88, 0.70, respectively). Similarly, there was no significant difference in 1-, 3-, 5-year DFS rate between the combined group and the HR alone group (OR=0.57, 0.83, 0.72; P=0.17, 0.37, 0.32, respectively). And the intraoperative parameters and postoperative AEs were also comparable between the above two cohorts. However, two included studies reported that tumor often recurred in the ablation site in the combined group. The present meta-analysis indicated that the HR combined with RFA could reach a long-term survival outcome similar to curative HR for multifocal HCC patients. And this therapy may be a promising alternative for these patients with marginal liver function or complicated tumor distribution. Furthermore, high quality randomized controlled trials (RCTs) are imperative to verify this conclusion.
Similar content being viewed by others
References
Liu J, Fan D. Hepatitis B in China. Lancet, 2007,369(9573):1582–1583
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2016,2:16018
Omer RE, Kuijsten A, Kadaru AM, et al. Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma. Nutr Cancer, 2004,48(1):15–21
National Center for Health S. Health, United States. In Health, United States, 2014: With Special Feature on Adults Aged 55–64. Hyattsville (MD): National Center for Health Statistics (US) 2015.
Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma:epidemiology and clinical aspects. Mol Aspects Med 2008,29(1-2):130–143
de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol, 2012,56:S75–S87
Yi PS, Zhang M, Xu MQ. Management of the middle hepatic vein in right lobe living donor liver transplantation: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci, 2015,35(4):600–605
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011,53(3):1020–1022
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer, 2012,48(5):599–641
Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 2002,35(3):519–524
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002,359(9319):1734–1739
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008,359(4):378–390
Xu Q, Kobayashi S, Ye X, et al. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. Sci Rep, 2014,4:7252
Xu G, Qi FZ, Zhang JH, et al. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol, 2012,10:163
Wang JH, Wang CC, Hung CH, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol, 2012,56(2):412–418
Takayama T, Makuuchi M, Hasegawa K. Single HCC smaller than 2 cm: surgery or ablation?: surgeon's perspective. J Hepatobiliary Pancreat Sci, 2010,17(4):422–424
Choi D, Lim HK, Joh JW, et al. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol, 2007,14(12):3510–3518
Poon RT. Radiofrequency ablation combined with resection enhances chance for curative treatment of hepatocellular carcinoma. Ann Surg Oncol, 2007,14(12):3299–3300
Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol, 2003,10(9):1059–1069
Cheung TT. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: Prognosis and outcomes. World J Gastroenterol, 2010,16(24):3056
Yan J, Li X, XIA F. Survival analysis of radio frequency ablation combined with liver resection for dual lobe multifocal hepatocellular carcinoma. Abdom Surg, 2012,25(2):76–78
Lee SJ, Cho EH, Kim R, et al. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg, 2015,19(3):98–102
Zhang T, Zeng Y, Huang J, et al. Combined resection with radiofrequency ablation for bilobar hepatocellular carcinoma: a single-center experience. J Surg Res, 2014,191(2):370–378
Higgins JPT, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions (version 5.1.0). Chichester: John Wiley & Sons, Ltd, 2011:1–53
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010,25(9):603–605
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 2005,5:13
Hsu CY, Hsia CY, Huang YH, et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol, 2012,19(3):842–849
Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol, 2014,61(1):82–88
Hou YF, Wei YG, Yang JY, et al. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. Hepatobiliary Pancreat Diseas Internat, 2016,15(4):378–385
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by the grants from the National Natural Science Foundation of China (No. 71673193), and Key Technology Research and Development Program of the Sichuan Province (No. 2015SZ0131).
Rights and permissions
About this article
Cite this article
Xu, Ll., Zhang, M., Yi, Ps. et al. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. CURR MED SCI 37, 974–980 (2017). https://doi.org/10.1007/s11596-017-1836-3
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-017-1836-3